Search

Your search keyword '"Signol, N."' showing total 12 results
Start Over Author "Signol, N."
12 results on '"Signol, N."'

3. Equipe mobile gériatrique (EMG) extra hospitalière en Limousin : une expérience de collaboration entre une équipe mobile de gériatrie et une équipe mobile de psychiatrie du sujet âgé

Author

Signol, N, Vieban, F, Dantoine, Thierry, Guigout, C, Clément, Jean-Pierre, Lachal, Florent, Handicap, Activité, Vieillissement, Autonomie, Environnement (HAVAE), Institut Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST), Université de Limoges (UNILIM)-Université de Limoges (UNILIM), Service de Psychiatrie [CHU Limoges], CHU Limoges, Centre de Mémoire de Ressources et de Recherches [Limoges] (CMRR Limoges), and CHU Limoges-CH Esquirol [Limoges] (CH Esquirol)

Subjects
[SDV.MHEP.GEG] Life Sciences [q-bio]/Human health and pathology/Geriatry and gerontology, [SDV.MHEP.GEG]Life Sciences [q-bio]/Human health and pathology/Geriatry and gerontology, ComputingMilieux_MISCELLANEOUS
Abstract

National audience

Published
2012

12. Polypharmacy, potentially inappropriate medications and drug-drug interactions in geriatric patients with hematologic malignancy: Observational single-center study of 122 patients.

Author

Leger DY, Moreau S, Signol N, Fargeas JB, Picat MA, Penot A, Abraham J, Laroche ML, and Bordessoule D

Subjects
Aged, Aged, 80 and over, Female, Geriatric Assessment, Hematologic Neoplasms complications, Humans, Longitudinal Studies, Male, Medication Reconciliation organization & administration, Pharmacists, Potentially Inappropriate Medication List statistics & numerical data, Drug Interactions, Hematologic Neoplasms drug therapy, Polypharmacy
Abstract

Objectives: Geriatric patients with hematologic malignancies (HMs) are prescribed targeted and supportive care treatments that add to the preexisting polypharmacy (PP). PP is associated with an increased risk of potentially inappropriate medications (PIM) and drug-drug interactions (DDI) resulting in increased hospitalization and mortality in the elderly. As very few data exist on these medication issues in the context of HMs, the objective of this study was to evaluate prevalence of PP, DDI and PIM use at baseline and 3months among elderly patients with HMs who received baseline geriatric assessment., Methods: PP, DDI and PIM use were assessed by a clinical pharmacist at two time points in patients over 75years with HMs undergoing chemotherapy. PP was defined as the concurrent use of five or more medications. DDIs were evaluated according to the literature and prescription analysis software. PIMs were assessed according to the Laroche list., Results: 122 patients (mean age 81.5; 6.6 medications) were included and after 3months, 86 patients (5.8 medications) were available for a second assessment. Prevalence of PP, PIM and DDI at inclusion was 75.4%, 34.4% and 71.3%, respectively. PP was the only medication risk that was significantly reduced (p<0.05) at 3months (65.1%) compared to admission., Conclusion: This observational study highlighted that PP decreased over time but neither DDI nor PIM use were reduced. A pharmacist-led evaluation might help to manage these medication issues., (Copyright © 2017. Published by Elsevier Ltd.)

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results